8-K
filed October 12, 2023, 7:59 PM ET
ticker CATX
CIK 0000728387
other
confidence high
sentiment neutral
materiality 0.50
Shareholders approve equity plan boost: 10M more shares plus evergreen provision
Perspective Therapeutics, Inc.
- Approved Second Amended and Restated 2020 Equity Incentive Plan increasing authorized shares by 10M to 56M total.
- Added evergreen provision: each quarter, pool resets to greater of 56M shares or 13% of outstanding shares.
- Plan term extended to ten years from October 6, 2023 annual meeting date.
- Elected Lori A. Woods, Heidi Henson, Frank Morich, Johan Spoor, and Robert Williamson as directors.
- Ratified Assure CPA as independent auditor for FY 2023; votes: 157M for, 2.3M against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Perspective Therapeutics, Inc. shareholders approved Ratification of appointment of Assure CPA, LLC as independent registered public accounting firm at the 2023-10-06 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-10-06
Exact text from the filing
The stockholders of the Company ratified the appointment of Assure CPA, LLC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Perspective Therapeutics, Inc. shareholders approved Approval of Second Amended and Restated 2020 Equity Incentive Plan at the 2023-10-06 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-10-06
Exact text from the filing
The stockholders of the Company approved the Amended and Restated Plan.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Perspective Therapeutics, Inc. shareholders approved Election of Directors at the 2023-10-06 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-10-06
Exact text from the filing
The stockholders of the Company elected Lori A. Woods, Heidi Henson, Frank Morich, M.D., Ph.D., Johan (Thijs) Spoor and Robert Froman Williamson, III to the Board to hold office until the Company’s 2024 Annual Meeting of Stockholders and until his or her successor has been elected and qualified.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.